BioMarin announced it will acquire Alesta Therapeutics in a $275 million deal, aiming to restock its late-stage rare bone-disorder pipeline after prior transaction churn. The Alesta buyout adds an experimental asset BioMarin said could reach its largest addressable patient population. The company framed the move as strengthening its muscle and skeletal disease portfolio, positioning the new program alongside existing internal development efforts. The acquisition follows earlier BioMarin activity around rare-disease assets and suggests the company is continuing to reposition for the next set of registrational catalysts. BioMarin’s challenge will be whether the Alesta asset can translate early signals into robust efficacy and safety—especially in a competitive rare bone landscape where differentiation and endpoints matter for payer acceptance.